High‑dose vitamin C as a metabolic treatment of cancer: a new dimension in the era of adjuvant and intensive therapy

• Xin Wang ^[2] ; Jia He ^[2] ; Minmin Sun ^[1] ; Shiwan Wang ^[2] ; Jinxiu Qu ^[2] ; Hanping Shi ^[2] ; Benqiang Rao ^[2]
  1. [1] Chinese Academy of Sciences

     Chinese Academy of Sciences

     China

     
  2. [2] Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 4, 2025, págs. 1366-1382
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The anti-cancer mechanism of High-dose Vitamin C (HDVC) is mainly to participate in the Fenton reaction, hydroxylation reaction, and epigenetic modifcation, which leads to the energy crisis, metabolic collapse, and severe peroxidation stress that results in the proliferation inhibition or death of cancer cells. However, the mainstream view is that HDVC does not signifcantly improve cancer treatment outcomes. In clinical work and scientifc research, we found that some drugs or therapies can signifcantly improve the anti-cancer efects of HDVC, such as PD-1 inhibitors that can increase the anti-cancer efects of cancerous HDVC by nearly three times. Here, the adjuvant and intensive therapy and synergistic mechanisms including HDVC combined application of chemoradiotherapies multi-vitamins, targeted drugs, immunotherapies, and oncolytic virus are discussed in detail. Adjuvant and intensive therapy of HDVC can signifcantly improve the therapeutic efect of HDVC in the metabolic treatment of cancer, but more clinical evidence is needed to support its clinical application.